PRESS RELEASE

Munich, April 27, 2026

honert advised the CERTANIA Group on the acquisition of InnoDiab Forschung GmbH.

CERTANIA Group, headquartered in Munich, is a leading global provider in the Testing, Inspection & Certification (TIC) sector. The Group offers testing, inspection, certification and consulting services for companies operating in regulated and quality critical markets. Within the TIC industry, CERTANIA focuses on five business areas: Life Sciences, Food & Consumer Goods, Industrials, Buildings & Infrastructure, and Certification & Compliance. This enables CERTANIA to cover key sectors in which safety, quality and compliance are critical. With this transaction, CERTANIA continues its international expansion strategy and strengthens its position as a growing global TIC player.

About InnoDiab: The Essen-based company has many years of experience in conducting clinical trials on diabetes and its associated metabolic, cardiovascular, renal and neurological conditions. Its work focuses on evaluating the efficacy and tolerability of new medicines for diabetes treatment, as well as testing new technologies. The company’s approach combines high-quality patient care with innovative clinical research methods, thereby helping to tackle the growing epidemic of diabetes.

Both parties have agreed not to disclose the details of the transaction.

ADVISORS TO THE CERTANIA GROUP:

honert (Munich): Patrick Spalek (lead), Verena Wackerbauer, Felix Strobel, Samuel Wimmer (all corporate law, M&A)